SCHEMBL375190

SCHEMBL375190

c1cnc2c(n1)NCCO2

nearest known ligand 0.36

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 3/20 0.36
RET P07949 4/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5760246 0.75 GRM5 (0.36) GRM5RET
SCHEMBL1808178 0.72 GRM5 (0.34) GRM5RET
SCHEMBL17184734 0.72 GRM5 (0.37) GRM5RET
SCHEMBL16985088 0.71 FABP6 (0.37)
SCHEMBL30832288 0.69 RET (0.36) GRM5RET
SCHEMBL18529197 0.69 GRM5 (0.32) GRM5
SCHEMBL31712943 0.68 CHEK1 (0.37) RET
SCHEMBL5756757 0.68 CHEK1 (0.37) RET
SCHEMBL1093026 0.68 GRM5 (0.50) GRM5
SCHEMBL304791 0.68 GRM5 (0.46) GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 538 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1852420-B1 Indole compounds for treating respiratory disorders ONO PHARMACEUTICAL CO (JP) 2012-10-17 EP claimed
US-8153625-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2012-04-10 US claimed
US-7759336-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2010-07-20 US claimed
US-7402580-B2 Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-07-22 US claimed
US-7101869-B2 2,4-diaminopyrimidine compounds useful as immunosuppressants PFIZER INC. (US) 2006-09-05 US claimed
EP-1242403-B1 2,4-DIAMINOPYRIMIDINE COMPOUNDS USFUL AS IMMUNOSUPPRESSANTS PFIZER PROD INC (US) 2006-01-04 EP claimed
US-20030191307-A1 2,4-Diaminopyrimidine compounds useful as immunosuppressants BLUMENKOPF TODD A (US) 2003-10-09 US claimed
CN-1402720-A 2,4-diaminopyrimidine compounds useful as immunosuppressants PFIZER PROD INC (US) 2003-03-12 CN claimed
US-12630510-B2 EP2 antagonist ONO PHARMACEUTICAL CO., LTD. (JP) 2026-05-19 US disclosed
EP-4727924-A1 INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION ONO Pharmaceutical Co., Ltd. (JP) 2026-04-22 EP disclosed
US-12600730-B2 Substituted cyclopenta[c]pyrroles as ABHD6 antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2026-04-14 US disclosed
US-20260083735-A1 ABHD6 ANTAGONIST ONO PHARMACEUTICAL CO., LTD. (JP) 2026-03-26 US disclosed
EP-4682141-A1 TRICYCLIC COMPOUND ONO Pharmaceutical Co., Ltd. (JP) 2026-01-21 EP disclosed
US-12497377-B2 Tricyclic spiro compound ONO PHARMACEUTICAL CO., LTD. (JP) 2025-12-16 US disclosed
EP-1424335-A1 INDOLE DERIVATIVES ONO PHARMACEUTICAL CO., LTD. (JP) 2004-06-02 EP disclosed
EP-1417975-A1 REMEDIES FOR DISEASES WITH BONE MASS LOSS HAVING EP sb 4 /sb AGONIST AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-05-12 EP disclosed
US-20040063936-A1 Pyrimidine derivatives and process for preparing the same ONO PHARMACEUTICAL CO., LTD. (JP) 2004-04-01 US disclosed
EP-1354879-A1 DIHYDRONAPHTHALENE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2003-10-22 EP disclosed
US-20030191307-A1 2,4-Diaminopyrimidine compounds useful as immunosuppressants BLUMENKOPF TODD A (US) 2003-10-09 US disclosed
EP-1346985-A1 PYRIMIDINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2003-09-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030191307-A1 2,4-Diaminopyrimidine compounds useful as immunosuppressants CCR1, AOC1, NOD1 GRM5 3933/4885RET 4326/4885
US-12630510-B2 EP2 antagonist PTGER2, PTGER1, PTGER4 GRM5 385/4885RET 1979/4885
US-12497377-B2 Tricyclic spiro compound PTGER4, PTGER1, PTGER3 GRM5 874/4885RET 1321/4885
US-20040063936-A1 Pyrimidine derivatives and process for preparing the same DPYD, NUDT1, UMPS GRM5 3972/4885RET 2729/4885
US-12600730-B2 Substituted cyclopenta[c]pyrroles as ABHD6 antagonists ABHD6, ABHD16A, HDHD5 GRM5 3523/4885RET 4586/4885
US-20260083735-A1 ABHD6 ANTAGONIST ABHD6, ABHD16A, ABHD12 GRM5 2693/4885RET 4652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.